HOME >> BIOLOGY >> NEWS
Steroid-coated DNA represents new approach to gene delivery

PHILADELPHIA Coating DNA with a topical steroid might make for more effective therapeutic gene delivery, according to bioengineers at the University of Pennsylvania. The researchers have shown that a common anti-inflammatory steroid, wrapped around a strand of DNA, can prevent the immune responses commonly associated with gene-transfer techniques.

Studies of the technique, performed in animal models, are presented in the Feb. 15 issue of the journal Gene Therapy, available online now.

"The steroid coating not only allows the gene to be taken up into a cell more easily, but the steroid itself also prevents the sort of inflammatory immune response seen in gene transfer therapy," said Scott Diamond, senior author and professor of bioengineering at Penn and associate director of Penn's Institute for Medicine and Engineering. "The concept paves the way to coupling therapeutic gene delivery with a pharamacological agent, an approach that mitigates some of the drawbacks to the gene-delivery techniques in use now."

Currently there are two basic approaches to delivering therapeutic genes: nonviral and viral. Injecting a subject with pure DNA is possible, but a DNA molecule, by itself, has inherent trouble in entering cells. Viral carriers can serve as delivery vehicles for DNA, literally infecting cells with new genes. Both methods, however, are associated with the creation of inflammatory immune responses that reduces the action of the therapeutic gene.

DNA is a large and negatively charged molecule, which is the source of the stumbling point in getting cells to take up DNA. To counter the negative charge of DNA, Diamond and his colleagues took a common steroid, dexamethasone, and made it "sticky" by adding a nitrogen-rich, postively charged tail. This tail provides the glue that attaches the steroid to the naked DNA.

"The steroid is a fatty lipid so, in essense, we have greased up DNA for cellular uptake," Diamond said,
'"/>

Contact: Greg Lester
glester@pobox.upenn.edu
215-573-6604
University of Pennsylvania
11-Feb-2004


Page: 1 2

Related biology news :

1. Belgian researchers explore revolutionary approach to angiogenesis
2. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
3. Researchers recommend new approach to combat drug-resistant staph infections
4. U. Iowa muscular dystrophy discovery may lead to new treatment approaches
5. New research suggests therapeutic approach for autoimmune diseases
6. New approach offers potential drug-discovery shortcut
7. New approach limits damage after heart attack and improves survival, say Scripps Research scientists
8. Two-drug approach might shorten painful labor, reduce Caesarean sections
9. Death-defying approach devised by Penn scientists to prevent cell apoptosis
10. Smallpox in 50-year-old tissues detected by integrated diagnostics approach
11. One-size-fits-all approach to nutrition recommendations may soon be outdated

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Steroid coated DNA represents new approach gene delivery

(Date:10/16/2014)... tract infections and worldwide claims the lives of ... Ghent University have succeeded in developing a promising ... , Xavier Saelens (VIB/UGent): "We discovered a ... the development of a novel approach to vaccination ... numerous small children and elderly people." , ...
(Date:10/15/2014)... 15, 2014 Sandata Technologies, LLC, an ... community-based care, today announced it released a case ... Electronic Visit Verification™ Solution (EVV™)  for Quality Care ... health company founded in 1996 and has five ... The study details the challenges facing ...
(Date:10/15/2014)... has admitted Johannes Gutenberg University Mainz (JGU) as ... hub continues to maintain a significant nationwide standing ... "The acceptance of Johannes Gutenberg University Mainz as ... milestone in the national and international competition for ... of Rhineland-Palatinate can be proud that Mainz University ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2Sandata Announces Case Study with Quality Care Services, Inc. 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
(Date:10/22/2014)... SAN DIEGO and HONG KONG ... an innovative rare disease therapeutics enterprise, announced today that ... joined the company as vice president, research. Dr. McKew ... research, including key leadership positions at the National Institutes ... to its acquisition by Wyeth). Dr. McKew will lead aTyr,s ...
(Date:10/20/2014)... Oct. 20, 2014 Asterias Biotherapeutics, Inc. ... has signed a Notice of Grant Award (NGA) ... effective October 1, 2014.  The NGA provides for ... the release of additional grant funds pursuant to ... for clinical development of Asterias, product, AST-OPC1. The ...
(Date:10/20/2014)... 20, 2014 PureTech , a science ... healthcare problems, announced today the closing of a ... from Invesco Perpetual, a $120 Billion group of ... PureTech,s existing pipeline forward and to advance new ... scientific creativity to really go for the big ...
(Date:10/19/2014)... The Latin American hardware encryption display market report defines ... and forecast of revenue. This market was valued at ... $2,366.8 million by 2018, at a CAGR of 70.3% ... of the Latin American hardware encryption market report to ... also provides a glimpse of the segmentation of the ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
Cached News: